An observational study in Diabetes Mellitus and Covid19, sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Recruiting at 1 site in Mexico. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-03-08.
Sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Observational
DM2 is a major comorbidity of COVID-19. It has been observed that subjects with DM2 require more medical interventions, have a significantly higher mortality (7.8% versus 2.7%) and injuries of multiple organs that the individuals not diabetics.
In situations of glycemic variability, phenomena of oxidative stress and activation of protein kinase C can be initiated , through the release of pro-inflammatory cytosines , which could induce microvascular damage .Patients with diabetes and COVID-19 were shown to be more likely to develop serious or critical illness with more complications, and to have higher incidence rates of antibiotic therapy, non-invasive and invasive mechanical ventilation, and death (11.1% vs. 4.1%).
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's planned enrollment of 120 is below the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran is the lead sponsor of 141 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults living with diabetes and suffering from COVID19 pneumonia
Exclusion Criteria:
Glucose variability
Percentage of time within the ADA recommended range
Time frame: For up to two weeks, during hospitalization
Insulin use
Average daily UI of insulin per patient
Time frame: For up two weeks, during hospitalization
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran